Aptuit | Our history

Our history

Evolving drug development since 2004

Established in 2004, Aptuit’s aim has always been to truly partner pharmaceutical and biotech companies in accelerating innovation of the highest quality. Today, we are a market leader on a global scale. Our history is one of investing in the future by putting together an unrivalled suite of drug development solutions, from discovery to commercialization.

Aptuit | history


Evotec acquire Aptuit to form the premier drug discovery and development innovation partner by leveraging both companies' extensive partner networks, platforms and maximising commercial synergies. Aptuit is now an Evotec company. (Aug 11, 2017)

Aptuit names Henning Steinhagen as President, Research and Development Operations (Apr 6, 2017)


Aptuit names Peter Gray as the new Chairman of Aptuit Holdings, LLC (Nov 28, 2016)

Aptuit acquire Exquiron, a leading specialist Contract Research Organization dedicated to early phase drug discovery solutions.

Aptuit acquire Kuecept, a specialist drug pre-formulation, formulation prototyping and formulation development services Contract Research Organization.


Jonathan Goldman is invited to join the Columbia University Healthcare Advisory Board

Aptuit is appointed as a member of EU-NETVAL


Jonathan Goldman is named Aptuit's CEO


Catalent acquires the Clinical Trial Supplies business of Aptuit. Aptuit now focusses its efforts on its market-leading integrated discovery to mid-phase development business.


On July 1st the GlaxoSmithKline Medicines Research Centre in Verona, Italy, becomes part of Aptuit as a strategic acquisition to further strengthen scientific expertise and capabilities. The partnership represents a unique development of new models of outsourced R&D collaborations.


Tim Tyson is appointed Executive Chairman and CEO


Aptuit secures $100M internal investment and closes new important acquisition deals with EaglePitcher and Evotec that allow expanding presence in the United Kingdom, with sites in Oxford and Glasgow, and in the United States, with a site in Missouri and the Solid State Chemistry Institute (SSCI) in Indiana. 

A joint venture in June 2007 between Aptuit, Inc. and Laurus Labs will create Aptuit Laurus, which combined Aptuit’s expertise in drug development with Laurus’ R&D and manufacturing expertise and world-class facilities.


The company consolidate presence, secure private equity investment and expand capabilities. Major acquisitions include InfoPro and PharmaConsulting Inc.


GPD becomes Aptuit in July 2005. Aptuit’s name is derived from the words aptitude and intuition, two natural attributes that characteristically define the company’s unique approach to providing comprehensive drug discovery and development support.

The company announces agreements for acquisition of Almedica and Quintiles EDP. Both acquisitions are closed within October. The company has sites in UK, North America and Singapore


Aptuit, initially named GPD, was founded in 2004 by a group of industry experts with extensive market experience and a track record of building a similar, highly successful business through acquisition and investment. The headquarters site was established in Greenwich, CT. Initial funding by Welsh, Carson, Anderson, & Stowe